

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **March 22, 2021**

**SILICON LABORATORIES INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-29823**  
(Commission File Number)

**74-2793174**  
(IRS Employer  
Identification No.)

**400 West Cesar Chavez, Austin, TX**  
(Address of Principal Executive Offices)

**78701**  
(Zip Code)

Registrant's telephone number, including area code: **(512) 416-8500**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, \$0.0001 par value	SLAB	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Exchange Act of 1934.

---

---

### **Item 3.02 Unregistered Sales of Equity Securities.**

On January 6, 2021, Silicon Laboratories Inc. (the “Company”) issued a notice of redemption to the holders of its outstanding 1.375% Convertible Senior Notes due 2022 (the “Notes”), pursuant to which it would redeem all of the outstanding Notes for cash at a redemption price of 100% of the principal amount of the Notes, plus accrued and unpaid interest, if any (the “Redemption”). The Redemption was scheduled to occur on March 22, 2021, unless earlier converted. Prior to the consummation of the Redemption, the holders of the Notes were entitled to convert such Notes into shares of the Company’s common stock at a rate of 10.8856 shares per \$1,000 principal amount of Notes, which is equivalent to a conversion price of \$91.86 per share. Such conversion right expired on March 19, 2021 (the “Conversion Deadline”).

Prior to the Conversion Deadline, the Company received conversion notices from the holders of 92.73% of the Notes representing \$130.4 million outstanding principal amount thereof (the “Conversions”). In satisfaction of the conversion notices, the Company issued 528,022 shares of common stock to the holders of the Notes, as well as \$5 thousand in lieu of fractional shares, in accordance with the terms of the indenture governing the Notes. Notes representing \$10.2 million outstanding principal amount were redeemed at par, plus accrued interest. Upon the Company’s settlement of the Conversions and Redemption, all of the Notes ceased to be outstanding, principal ceased to accrete and the entire principal amount of the Notes was deemed paid in full, interest ceased to accrue and all accrued and unpaid interest on the Notes was deemed paid in full, and all rights of holders of the Notes terminated. The Company relied upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended, and upon similar exemptions under applicable state laws, in connection with the Conversions.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SILICON LABORATORIES INC.

March 23, 2021

---

Date

/s/ John C. Hollister

---

John C. Hollister  
*Senior Vice President and  
Chief Financial Officer  
(Principal Financial Officer)*

---